search
Back to results

Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women (VICAR2)

Primary Purpose

Cervical Intraepithelial Neoplasia

Status
Completed
Phase
Not Applicable
Locations
South Africa
Study Type
Interventional
Intervention
Cryotherapy
LEEP
Sponsored by
University of Witwatersrand, South Africa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Intraepithelial Neoplasia focused on measuring Cervical Dysplasia, Cin 2, Cin 3, HIV positive women, South Africa

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women 18-65 years of age
  • Not menstruating (if menstruating, the patient can be screened at another date)
  • Able to sign consent
  • Able to follow the study protocol
  • HIV positive (by two different criteria; either 2 different rapid HPV tests of different manufacturers, a HIV viral load ≥5,000,ELISA, Western blot documented in VICAR 1)
  • Participant with histology-proven CIN 2 or 3 disease

Exclusion Criteria:

  • Pregnant
  • Clinically active sexually transmitted disease determined by clinical history and/or physical exam (may participate after adequate treatment by syndromic treatment management)
  • Known and previous treatment for high grade squamouse intraepithelial lesion by any method (cryotherapy, LLETZ or cone biopsy)
  • Previous hysterectomy with removal of the cervix
  • Significant medical illness/mental illness that the investigator feels would prevent the participant from complying with the protocol or place the participant at medical risk
  • Cervical dysplastic lesions that are not appropriate for cryotherapy, defined as the following:

    1. Lesion is greater than ≥75% cervix
    2. Lesion entering into the cervical canal and the complete lesion cannot be visualized
    3. Presence of abnormal vasculature
    4. Lesion bigger that the cryotherapy probe

Sites / Locations

  • Helen Joseph Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Arm B

Arm A

Arm Description

LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)

Cryotherapy treatment of CIN 2/3 cervical lesions

Outcomes

Primary Outcome Measures

Compare efficacy of cryotherapy and LEEP
To compare the efficacy of cryotherapy and large loop excision of the transformation zone (LLETZ) procedures for the treatment of high-grade cervical intra-epithelial neoplasia (CIN2/3) among HIV-seropositive women by follow-up VIA, cytology and HPV.

Secondary Outcome Measures

The ability to use Human Papillomavirus as the measure of treatment success
To determine the utility of subsequent HPV DNA testing as a marker of effective treatment following the treatment of CIN 2/3 among HIV-seropositive women.
To compare the safety of cryotherapy versus LLETZ in HIV seropositive women
To compare the safety of cryotherapy versus LLETZ in HIV seropositive women by evaluating adverse events as measured by the Division of AIDS toxicity table 2004 (revised August 2010)
Describe factors associated with successful treatment of CIN 2/3
To describe HIV disease status (CD4, HIV viral load), demographics, tissue margins and sexual behavior in each treatment arm (LLETZ and cryotherapy) in HIV seropositive women.
To determine the cervical disease recurrence rates with cryotherapy and LLETZ.
To determine the cervical disease recurrence rates with cryotherapy and LLETZ at 6 months and 12 months by colposcopy

Full Information

First Posted
November 6, 2012
Last Updated
September 19, 2014
Sponsor
University of Witwatersrand, South Africa
search

1. Study Identification

Unique Protocol Identification Number
NCT01723956
Brief Title
Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women
Acronym
VICAR2
Official Title
Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Witwatersrand, South Africa

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To compare the efficacy of cryotherapy and large loop excision of the transformation zone (LLETZ) procedures for the treatment of high-grade cervical intra-epithelial neoplasia (CIN2/3) among HIV-seropositive women by follow-up VIA, cytology and Human Papillomavirus. Hypothesis: LEEP will be more effective than cryotherapy in removing CIN 2/3 lesions in HIV positive women in South Africa
Detailed Description
Cervical cancer is the most common cancer in HIV positive women. This is due to immunosuppression and lack of organized and effective screening and treatment programs in Africa. Other screening and treatment modalities need to be evaluated in resource limited countries as there is not capacity in most of these countries to implement a cytology/histology based program. The treatment modality of cryotherapy is easy to train and perform and can be done by a nurse. LEEP requires significant training usually doctors and skills in administering local anaesthetic. This study compares the two modalities of cryotherapy vs LEEP in a randomized controlled study in HIV positive women in South Africa. A. PRIMARY AIMS (S.A.): To compare the efficacy of cryotherapy and large loop excision of the transformation zone (LLETZ) procedures for the treatment of high-grade cervical intra-epithelial neoplasia (CIN2/3) among HIV-seropositive women by follow-up VIA, cytology and HPV. To determine the utility of subsequent HPV DNA testing as a marker of effective treatment following the treatment of CIN 2/3 among HIV-seropositive women. To compare the safety of cryotherapy versus LLETZ in HIV seropositive women. SECONDARY AIMS: 1. To describe HIV disease status (CD4, HIV viral load), demographics, and sexual behavior in each treatment arm (LLETZ and cryotherapy) in HIV seropositive women. 3. To determine the cervical disease recurrence rates with cryotherapy and LLETZ. 4. To evaluate the relationship between HIV status, demographics, HPV, and sexual behavior with the clearance of cervical disease at the ectocervical and endocervical margins in HIV seropositive women.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Intraepithelial Neoplasia
Keywords
Cervical Dysplasia, Cin 2, Cin 3, HIV positive women, South Africa

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
166 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm B
Arm Type
Active Comparator
Arm Description
LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
Arm Title
Arm A
Arm Type
Experimental
Arm Description
Cryotherapy treatment of CIN 2/3 cervical lesions
Intervention Type
Procedure
Intervention Name(s)
Cryotherapy
Other Intervention Name(s)
This is a study using Freezing with a cryogun
Intervention Description
This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
Intervention Type
Procedure
Intervention Name(s)
LEEP
Other Intervention Name(s)
Loop Electric Excision Procedure
Intervention Description
The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
Primary Outcome Measure Information:
Title
Compare efficacy of cryotherapy and LEEP
Description
To compare the efficacy of cryotherapy and large loop excision of the transformation zone (LLETZ) procedures for the treatment of high-grade cervical intra-epithelial neoplasia (CIN2/3) among HIV-seropositive women by follow-up VIA, cytology and HPV.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
The ability to use Human Papillomavirus as the measure of treatment success
Description
To determine the utility of subsequent HPV DNA testing as a marker of effective treatment following the treatment of CIN 2/3 among HIV-seropositive women.
Time Frame
1 year
Title
To compare the safety of cryotherapy versus LLETZ in HIV seropositive women
Description
To compare the safety of cryotherapy versus LLETZ in HIV seropositive women by evaluating adverse events as measured by the Division of AIDS toxicity table 2004 (revised August 2010)
Time Frame
1 month, 6 months and 12 months
Title
Describe factors associated with successful treatment of CIN 2/3
Description
To describe HIV disease status (CD4, HIV viral load), demographics, tissue margins and sexual behavior in each treatment arm (LLETZ and cryotherapy) in HIV seropositive women.
Time Frame
1 year
Title
To determine the cervical disease recurrence rates with cryotherapy and LLETZ.
Description
To determine the cervical disease recurrence rates with cryotherapy and LLETZ at 6 months and 12 months by colposcopy
Time Frame
6 months and 12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women 18-65 years of age Not menstruating (if menstruating, the patient can be screened at another date) Able to sign consent Able to follow the study protocol HIV positive (by two different criteria; either 2 different rapid HPV tests of different manufacturers, a HIV viral load ≥5,000,ELISA, Western blot documented in VICAR 1) Participant with histology-proven CIN 2 or 3 disease Exclusion Criteria: Pregnant Clinically active sexually transmitted disease determined by clinical history and/or physical exam (may participate after adequate treatment by syndromic treatment management) Known and previous treatment for high grade squamouse intraepithelial lesion by any method (cryotherapy, LLETZ or cone biopsy) Previous hysterectomy with removal of the cervix Significant medical illness/mental illness that the investigator feels would prevent the participant from complying with the protocol or place the participant at medical risk Cervical dysplastic lesions that are not appropriate for cryotherapy, defined as the following: Lesion is greater than ≥75% cervix Lesion entering into the cervical canal and the complete lesion cannot be visualized Presence of abnormal vasculature Lesion bigger that the cryotherapy probe
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cynthia S Firnhaber, MD
Organizational Affiliation
University of Witwatersrand, South Africa
Official's Role
Principal Investigator
Facility Information:
Facility Name
Helen Joseph Hospital
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2092
Country
South Africa

12. IPD Sharing Statement

Citations:
PubMed Identifier
28366730
Citation
Smith JS, Sanusi B, Swarts A, Faesen M, Levin S, Goeieman B, Ramotshela S, Rakhombe N, Williamson AL, Michelow P, Omar T, Hudgens MG, Firnhaber C. A randomized clinical trial comparing cervical dysplasia treatment with cryotherapy vs loop electrosurgical excision procedure in HIV-seropositive women from Johannesburg, South Africa. Am J Obstet Gynecol. 2017 Aug;217(2):183.e1-183.e11. doi: 10.1016/j.ajog.2017.03.022. Epub 2017 Mar 31.
Results Reference
derived

Learn more about this trial

Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women

We'll reach out to this number within 24 hrs